| Title |
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
|
|---|---|
| Published in |
Clinical and Experimental Gastroenterology, May 2014
|
| DOI | 10.2147/ceg.s39518 |
| Pubmed ID | |
| Authors |
Anne Tuskey, Brian W Behm |
| Abstract |
The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn's disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα therapy represents a common clinical challenge, and highlights the need for the development of additional medication options for CD. The proinflammatory cytokines interleukin (IL)-12 and IL-23 are thought to play a key role in the pathogenesis of CD, and serve as a potential target for additional biologic therapies. Monoclonal antibodies targeting IL-12/23 have shown efficacy in animal models of colitis, and are currently being studied in Phase III clinical trials of CD. This review focuses on ustekinumab, a fully human immunoglobulin G1 monoclonal antibody, which blocks activity of IL-12 and IL-23 through binding the p40 subunit, and describes the current efficacy and safety data for ustekinumab in patients with CD. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 19% |
| Other | 8 | 14% |
| Researcher | 7 | 12% |
| Student > Postgraduate | 6 | 11% |
| Student > Bachelor | 5 | 9% |
| Other | 11 | 19% |
| Unknown | 9 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 54% |
| Agricultural and Biological Sciences | 3 | 5% |
| Immunology and Microbiology | 3 | 5% |
| Computer Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 7 | 12% |
| Unknown | 8 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#7,430,186
of 25,584,565 outputs
Outputs from Clinical and Experimental Gastroenterology
#105
of 311 outputs
Outputs of similar age
#66,999
of 242,530 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#4
of 9 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 311 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,530 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.